Emerald Mutual Fund Advisers Trust Raises Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Emerald Mutual Fund Advisers Trust grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 75.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 219,275 shares of the company’s stock after buying an additional 94,034 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in TransMedics Group were worth $13,672,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Atlas Capital Advisors Inc. purchased a new position in shares of TransMedics Group during the fourth quarter valued at approximately $31,000. Hager Investment Management Services LLC bought a new position in TransMedics Group in the fourth quarter worth approximately $33,000. Sachetta LLC bought a new stake in shares of TransMedics Group during the 4th quarter valued at $40,000. AlphaQuest LLC purchased a new stake in shares of TransMedics Group in the 4th quarter worth $52,000. Finally, Arcadia Investment Management Corp MI bought a new position in TransMedics Group in the 4th quarter worth $72,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 3.5 %

Shares of NASDAQ TMDX opened at $90.19 on Tuesday. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 95.95 and a beta of 2.14. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The business’s 50 day moving average price is $74.67 and its 200-day moving average price is $77.10. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.